Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5667_Библиотеки_им_академика_М_И_Перельмана

.pdf
Скачиваний:
0
Добавлен:
15.09.2026
Размер:
10 Мб
Скачать
☆
10 Carbohydrates and Carbohydrate-Based Therapeutics in Alzheimer’s Disease
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
346
GalNAc N-acetyl glucosamine
glycosaminoglycans
GAGs GalNAc-Ts GlcN HE
hematoxylin and eosin
HEXA
HEXB
HIV hOGA ICV IL
interleukin
IPA
inhibition constant
K
i
LCMS log D m-GluR5 miRCD33 microRNA MOM MTT
GalNAc-transferases
glucosamine
gene encoding for hexosaminidase subunit alpha
gene encoding for hexosaminidase subunit beta
human immunodeficiency virus
human P-GlcNAcase
intracerebroventricular
isopropyl alcohol
liquid chromatography–mass spectrometry
pH-dependent distribution constant
metabotropic glutamate receptor 5
microRNA targeting CD33
micro ribonucleic acid
methoxymethyl ether
(3- (4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-
tetrazolium bromide) NA-COS N-acetyl COS NCS
N-chlorosuccinimide
neurofibrillary tangles
NFTs NIS
N-iodosuccinimide
N-methyl--aspartate receptor
NMDA NMR
nuclear magnetic resonance
O-GlcNAcase
OGA OGT
O-GlcNAc transferase PAIN pan-assay interference compound PAMPA parallel artificial membrane permeability assay PCC pyridinium chlorochromate PCR polymerase chain reaction PET positron emission tomography PGs proteoglycans PivCl pivaloyl chloride
log10 of the acid dissociation constant, K
pK
a
PMBCl 4-methoxybenzyl chloride PNNs perineural nets PPTS pyridinium p-toluenesulfonate PrP prion protein
C
cellular prion protein
PrP
Sc
Scrapie isoform of the prion protein
PrP PUGNAc 2- Acetamido-2-deoxy--glucono-1,5-lactone
O-(phenylcarbamoyl)oxime
a
References
Py pyridine PyBOP be nzotriazol-1-yloxytripyrrolidinophosphonium
hexafluorophosphate SAR structure–activity relationships Ser serine
Ar nucleophilic aromatic substitution
S
N
STD saturation transfer difference STZ streptozotocin TBDMSCl tert-butyldimethylsilyl chloride TBSCl tert-butyldimethylsilyl chloride TBSOTf tert-butyldimethylsilyl trifluoromethanesulfonate TFA trifluoroacetic acid THF tetrahydrofuran THP tetrahydropyran Thr threonine TIPSCl triisopropylsilyl chloride TMSOTf trimethylsilyl trifluoromethanesulfonate TNF tumor necrosis factor TPHB triphenylphosphine hydrobromide TPSA topological polar surface area UDP uridine diphosphate
347
Acknowledgments
The authors wish to thank Fundação para a Ciência e a Tecnologia, Portugal, for supporting Centro de Química Estrutural (projects UIDB/00100/2020 e UIDP/ 00100/2020) and the Institute of Molecular Sciences (project LA/P/0056/2020). Ana Marta de Matos wishes to thank FCT for funding through the Individual Call for Scientific Employment Stimulus (2022.07037.CEECIND).
References
1 Varki, A. (2017). Glycobiology 27: 3–49. 2 Lin, B., Qing, X., Liao, J., and Zhuo, K. (2020). Cell 9: 1022. 3 Kappler, K. and Hennet, T. (2020). Genes and Immunity 21: 224–239. 4 Schnaar, R.L. (2015). The Journal of Allergy and Clinical Immunology 135:
609–615.
5 Sun, L., Middleton, D.R., Wantuch, P.L. etal. (2016). Glycobiology 26: 1029–1040. 6 Wani, W.Y., Chatham, J.C., Darley-Usmar, V. etal. (2017). Brain Research Bulletin
133: 80–87.
7 Estevez, A., Zhu, D., Blankenship, C., and Jiang, J. (2020). Chemistry- A European
Journal 26: 12086–12100.
10 Carbohydrates and Carbohydrate-Based Therapeutics in Alzheimer’s Disease
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
348
8 Alzheimer’s Disease International. Numbers of people with dementia around the
world, 2020. Available at: https://www.alzint.org/u/numbers-
people- with-
dementia- 2017.pdf (accessed on June 1 2023).
9 Demetrius, L.A., Magistretti, P.J., and Pellerin, L. (2015). Frontiers in
Physiology 5: 522.
10 Karran, E., Mercken, M., and De Stropper, B. (2011). Nature Reviews Drug
Discovery 10: 698–712.
11 Nygaard, H.B. (2018). Biological Psychiatry 83: 369–376. 12 Um, J.W. and Strittmatter, S.M. (2013). Prion 7: 37–41. 13 Smith, L.M., Zhu, R., and Strittmatter, S.M. (2018). Neuropharmacology
130: 54–61.
14 Lin, C., Chen, E.H.-L., Lee, L.Y.-L. etal. (2014). Carbohydrate Research 387: 46–53. 15 Dias, C. and Rauter, A.P. (2015). RSC Drug Discovery Series 43: 180–208. 16 Bajad, N.G., Swetha, R., Gutti, G. etal. (2021). Future Medicinal Chemistry 13 (19):
1695–1711.
17 Ryan, P., Patel, B., Makwana, V. etal. (2018). ACS Chemical Neuroscience 9:
1530–1551.
18 Nordberg, A. and Svensson, A.-L. (1998). Drug Safety 19: 465–479. 19 Hitzeman, N. (2006). American Family Physician 74 (5): 747–749. 20 Lombard, V., Golaconda Ramulu, H., Drula, E. etal. (2014). Nucleic Acids
Research 42: D490–D495.
21 Rexach, J.E., Clark, P.M., Mason, D.E. etal. (2012). Nature Chemical Biology 8:
253–261.
22 Francisco, H., Kollins, K., Varghis, N. etal. (2009). Developmental Neurobiology 69:
162–173.
23 Lagerlöf, O., Hart, G.W., and Huganir, R.L. (2017). Proceedings. of the National
Academy of Sciences of the United States of America 114: 1684–1689.
24 Wang, A.C., Jensen, E.H., Rexach, J.E. etal. (2016). Proceedings of the National
Academy of Sciences of the United States of America 113: 15120–15125.
25 Yuzwa, S.A. and Vocadlo, D.J. (2014). Chemical Society Reviews 43: 6839–6858. 26 Kim, C., Nam, D.W., Park, S.Y. etal. (2013). Neurobiology of Aging 34: 275–285. 27 Ryan, P., Xu, M., Davey, A.K. etal. (2019). ACS Chemical Neuroscience 10:
2209–2221.
28 Arnold, C.S., Johnson, G.V.W., Cole, R.N. etal. (1996). The Journal of Biological
Chemistry 271: 28741–28744.
29 Di Domenico, F., Chiara Lanzillotta, C., and Tramutola, A. (2019). Expert Review
of Neurotherapeutics 19: 1–3.
30 Drzezga, A., Lautenschlager, N., Siebner, H. etal. (2003). European Journal of
Nuclear Medicine and Molecular Imaging 30: 1104–1113.
31 Sancheti, H., Akopian, G., Yin, F. etal. (2013). PLoS One 8: e69830. 32 Sancheti, H., Kanamori, K., Patil, I. etal. (2014). Journal of Cerebral Blood Flow
and Metabolism 34: 288–296.
33 Chow, V.W., Mattson, M.P., Wong, P.C., and Gleichmann, M. (2010).
Neuromolecular Medicine 12 (1): 1–12.
References
34 Akasaka-Manya, K., Kawamura, M., Tsumoto, H. etal. (2017). Journal of
Biochemistry 161 (1): 99–111.
35 Gong, C.X., Liu, F., and Iqbal, K. (2016). Alzheimer’s & Dementia 12: 1078–1089. 36 Liu, F., Shi, J., Tanimukai, H. etal. (2009). Brain 132: 1820–1832. 37 Frenkel-Pinter, M., Shmueli, M.D., Raz, C. etal. (2017). Science Advances 3:
e1601576.
38 Hurtado-Guerrero, R., Dorfmueller, H.C., and van Aalten, D.M.F. (2008). Current
Opinion in Structural Biology 18: 551–557.
39 Macauley, M.S., Whitworth, G.E., Debowski, A.W. etal. (2005). The Journal of
Biological Chemistry 280: 25313–25322.
40 Cekic, N., Heinonen, J.E., Stubbs, K.A. etal. (2016). Journal of Chemical Sciences
7: 3742–3750.
41 Li, B., Li, H., Hu, C.-W., and Jiang, J. (2017). Nature Communications 8: 666. 42 Xiong, J. and Xu, D. (2020). The Journal of Physical Chemistry B 124: 9310–9322. 43 Liu, T., Duan, Y., and Yang, Q. (2018). Biotechnology Advances 36: 1127–1138. 44 Hattie, M., Cekic, N., Debowski, A.W. etal. (2016). Organic & Biomolecular
Chemistry 14: 3193–3197.
45 Beer, D., Maloisel, J.-L., Rast, D.M., and Vasella, A. (1990). Helvetica Chimica Acta
73: 1918–1922.
46 Beer, D. and Vasella, A. (1985). Helvetica Chimica Acta 68: 2254–2274. 47 Horsch, M., Hoesch, L., Vasella, A., and Rast, D.M. (1991). European Journal of
Biochemistry 197: 815–818.
48 Mohan, H. and Vasella, A. (2000). Helvetica Chimica Acta 83: 114–118. 49 Stubbs, K.A., Zhang, N., and Vocadlo, D.J. (2006). Organic & Biomolecular
Chemistry 4: 839–845.
50 Goddard-Borger, E.D. and Stubbs, K.A. (2010). The Journal of Organic Chemistry
75: 3931–3934.
51 Stubbs, K.A., Macauley, M.S., and Vocadlo, D.J. (2009). Angewandte Chemie 121:
1326–1329.
52 Dorfmueller, H.C., Borodkin, V.S., Schimpl, M. etal. (2006). Journal of the
American Chemical Society 128: 16484–16485.
53 Dorfmueller, H.C., Borodkin, V.S., Schimpl, M., and van Aalten, D.M.F. (2009).
The Biochemical Journal 420: 221–227.
54 Dorfmueller, H.C., Borodkin, V.S., Schimpl, M. etal. (2010). Chemistry & Biology
17 (11): 1250–1255.
55 Aoyagi, T., Suda, H., Uotani, K. etal. (1992). The Journal of Antibiotics 45:
1404–1408.
56 Heightman, T.D. and Vasella, A.T. (1999). Angewandte Chemie International
Edition 38: 750–770.
57 Perreira, M., Kim, J.E., Thomas, C.J., and Hanover, J.A. (2006). Bioorganic &
Medicinal Chemistry 14: 837–846.
58 Rao, F.V., Dorfmueller, H.C., Villa, F. etal. (2006). The EMBO Journal 25 (7):
1569–1578.
59 Borodkin, V.S. and van Aalten, D.M.F. (2010). Tetrahedron 66: 7838–7849.
349
10 Carbohydrates and Carbohydrate-Based Therapeutics in Alzheimer’s Disease
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
350
60 Gao, Y., Wells, L., Comer, F.I. etal. (2001). The Journal of Biological Chemistry 276:
9838–9845.
61 Yuzwa, S.A., Macauley, M.S., Heinonen, J.E. etal. (2008). Nature Chemical Biology
4: 483–490.
62 Yuzwa, S.A., Shan, X., Jones, B.A. etal. (2014). Molecular Neurodegeneration 9: 42. 63 Morrison, J.F. (1969). Biochimica et Biophysica Acta 185: 269–286. 64 Copeland, R.A. (2005). Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide
for Medicinal Chemists and Pharmacologists. Hoboken, New Jersey: John Wiley and Sons Inc.
65 Kuzmic, P., Elrod, K.C., Cregar, L.M. etal. (2000). Analytical Biochemistry
286: 45–50.
66 Perrin, L.C. and Fabian, M.A. (1996). Analytical Chemistry 68: 2127–2134. 67 Selnick, H.G., Hess, J.F., Tang, C. etal. (2019). Journal of Medicinal Chemistry 62:
10062–10097.
68 Sandhu, P., Lee, J., Ballard, J. etal. (2016). Alzheimer’s & Dementia 12: P1028. 69 Wang, X., Li, W., Marcus, J. etal. (2020). The Journal of Pharmacology and
Experimental Therapeutics 374: 252–263.
70 Akasaka-Manya, K. and Manya, H. (2020). Biomolecules 10: 1569. 71 Liu, F., Xu, K., Xu, Z. etal. (2017). The Journal of Biological Chemistry 292:
21304–21319.
72 Baig, S., Wilcock, G.K., and Love, S. (2005). Acta Neuropathologica 110: 393–401. 73 Testa, D., Prochiantz, A., and Di Nardo, A.A. (2019). Seminars in Cell &
Developmental Biology 89: 125–135.
74 Duce, J.A., Zhu, X., Jacobson, L.H., and Beart, P.M. (2019). British Journal of
Pharmacology 176: 3409–3412.
75 Duncan, J.A., Foster, R., and Kwok, J.C.F. (2019). British Journal of Pharmacology
176: 3611–3621.
76 Fonseca-Santos, B. and Chorilli, M. (2017). Materials Science & Engineering. C,
Materials for Biological Applications 77: 1349–1362.
77 Naveed, M., Lucas Phil, L., Sohail, M. etal. (2019). International Journal of
Biological Macromolecules 129: 827–843.
78 Kim, M.-S., Sung, M.-J., Seo, S.-B. etal. (2002). Neuroscience Letters 321: 105–109. 79 Jiang, Z., Liu, G., Yang, Y. etal. (2019). Process Biochemistry 84: 161–171. 80 Zameer, S., Ali, J., Vohora, D. etal. (2021). Journal of Drug Targeting 29: 199–216. 81 More, S.V., Kumar, H., Cho, D.-Y. etal. (2016). International Journal of Molecular
Sciences 17: 1447.
82 Kumar, A., Pintus, F., Di Petrillo, A. etal. (2018). Scientific Reports 8: 4424. 83 Mushtaq, G., Greig, N.H., Khan, J.A., and Kamal, M.A. (2014). CNS & Neurological
Disorders Drug Targets 13: 1432–1439.
84 Bartus, R.T., Dean, R.L., Beer, B., and Lippa, A.S. (1982). Science 217: 408–414. 85 Silver, A. (1974). The Biology of Cholinesterases. NewYork: American Elsevier
Pub. Co.
86 Greig, N.H., Utsuki, T., Ingram, D.K. etal. (2005). Proceedings of the National
Academy of Sciences of the United States of America 102: 17213–17218.
References
87 Sugimoto, H., Yamanishi, Y., Iimura, Y., and Kawakami, Y. (2000). Current
Medicinal Chemistry 7: 303–339.
88 Marcelo, F., Silva, F.V., Goulart, M. etal. (2009). Bioorganic & Medicinal Chemistry
17: 5106–5116.
89 Schwarz, S., Csuk, R., and Rauter, A.P. (2014). Organic & Biomolecular Chemistry
12: 2446–2456.
90 Xavier, N.M., Schwarz, S., Vaz, P.D. etal. (2014). European Journal of Organic
Chemistry 13: 2770–2779.
91 Batista, D., Schwarz, S., Loesche, A. etal. (2016). Pure and Applied Chemistry 2016
(88): 363–379.
92 Jasiecki, J., Targonska, M., and Wasag, B. (2021). International Journal of
Molecular Sciences 22: 2033.
93 Inestrosa, N.C., Alvarez, A., Perez, C.A. etal. (1996). Neuron 16: 881–889. 94 Inestrosa, N.C., Dinamarca, M.C., and Alvarez, A. (2008). The FEBS Journal 275:
625–632.
95 Rees, T.M. and Brimijoin, S. (2003). Drugs Today 39: 75–83. 96 Garcia-Ayllón, M.S., Small, D.H., and Sáez-Valero, J. (2011). Frontiers in Molecular
Neuroscience 4: 22.
97 Podoly, E., Bruck, T., Diamant, S. etal. (2008). Neurodegenerative Diseases 5:
232–236.
98 Podoly, E., Hanin, G., and Soreq, H. (2010). Chemico-Biological Interactions
197: 64–71.
99 Darvesh, S., Cash, M.K., Reid, G.A. etal. (2012). Journal of Neuropathology and
Experimental Neurology 71: 2–14.
100 Kumar, R., Nordberg, A., and Darreh-Shori, T. (2016). Brain 139: 174–192. 101 Kaufman, A.C., Salazar, S.V., Haas, L.T. etal. (2015). Annals of Neurology 77:
953–971.
102 Ford, J.G., Pointon, S.M., Powell, L. etal. (2010). Organic Process Research and
Development 14: 1078–1087.
103 Hennequin, L.F., Allen, J., Breed, J. etal. (2006). Journal of Medicinal Chemistry
49: 6465–6488.
104 Tang, S.J., Fesharaki-Zadeh, A., Takahashi, H. etal. (2020). Acta Neuropathologica
Communications 8: 96.
105 Matos, A.M., Blázquez-Sánchez, M.T., Bento-Oliveira, A. etal. (2020). Journal of
Medicinal Chemistry 63: 11663–11690.
106 Matos, A.M., Cristóvão, J.S., Yashunshy, D.V. etal. (2017). Pure and Applied
Chemistry 89: 1305–1320.
107 Matos, A.M., Martins, A., Man, T. etal. (2019). Pharmaceuticals 12: 98. 108 Matos, A.M., Man, T., Idrissi, T. etal. (2019). Pure and Applied Chemistry 91:
1107–1136.
109 Dias, C., Matos, A.M., Blásquez-Sanchez, M.T. etal. (2019). Pure and Applied
Chemistry 91: 1209–1221.
110 Neves, A.R., Nunes, C., Amenitsch, H., and Reis, S. (2016). Soft Matter 12:
2118–2126.
111 Baell, J.B. (2016). Journal of Natural Products 79: 616–628.
351
10 Carbohydrates and Carbohydrate-Based Therapeutics in Alzheimer’s Disease
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
352
112 Matos, A.M., Blázquez-Sánchez, M.T., Sousa, C. etal. (2021). Scientific Reports
11: 4443.
113 Jesus, A.R., Vila-Viçosa, D., Machuqueiro, M. etal. (2017). Journal of Medicinal
Chemistry 60: 568–579.
114 Jesus, R., Dias, C., Matos, A.M. etal. (2014). Journal of Medicinal Chemistry 57:
9463–9472.
115 Rudajev, V. and Novotny, J. (2020). Membranes 10: 226. 116 Matsuzaki, K. (2014). Accounts of Chemical Research 47: 2397–2404. 117 Kamiya, Y., Yagi-Utsumi, M., Yagi, H., and Kato, K. (2011). Current
Pharmaceutical Design 17: 1672–1684.
118 Ikeda, K. and Matsuzaki, K. (2008). Biochemical and Biophysical Research
Communications 370: 525–529.
119 Molander-Melin, M., Blennow, K., Bogdanovic, N. etal. (2005). Journal of
Neurochemistry 92: 171–182.
120 Loera-Valencia, R., Goikolea, J., Parrando-Fernandez, C. etal. (2019). The Journal
of Steroid Biochemistry and Molecular Biology 190: 104–114.
121 Jeong, W., Lee, H., Cho, S., and Seo, J. (2019). Molecules and Cells 42: 739–746. 122 Linnartz, B., Bodea, L.-G., and Neumann, H. (2012). Cell and Tissue Research 349:
215–227.
123 Salminen, A. and Kaarniranta, K. (2009). Journal of Molecular Medicine 87:
697–701.
124 Griciuc, A., Federico, A.N., Natasan, J. etal. (2020). Human Molecular Genetics 29:
2920–2935.
125 Dukhinova, M., Veremeyko, T., Yung, A.W.Y. etal. (2019). Neurobiology of Aging
77: 128–143.
126 Wißfeld, J., Nozaki, I., Mathews, M. etal. (2021). Glia 69: 1393–1412.
11
Carbohydrate-Based Antithrombotics
Antonella Bisio, Marco Guerrini, and Annamaria Naggi
Istituto di Ricerche Chimiche e Biochimiche G. Ronzoni, V. G. Colombo 81, Milan, 20133, Italy
11.1 Introduction
The history of carbohydrate-based antithrombotics began in Toronto about a cen­tury ago, with the chance discovery of heparin by Jay McLean and William Henry Howell[1, 2]. They had actually been looking for a procoagulant substance and suspected that their fat-soluble anticoagulant tissue extract might be a phospho­lipid. Despite their initial misinterpretation, the commercial potential of heparin was recognized immediately, and the first pharmaceutical heparin product appeared in the US market in 1939, produced by Roche Organon with the trade name Liquaemin. It was only in the early 1960s though, following the publication of a landmark clinical trial based on the use of heparin for the treatment of pulmonary embolism (PE)[3], that heparin was recognized as a powerful therapeutic drug for the prevention and treatment of venous thrombosis by intravenous administration. In the early 1970s, with the publication of a seminal paper by the group Kakkar, introducing the concept of subcutaneous administration of low-dose heparin for the prevention of postoperative deep vein thrombosis (DVT)[4], heparin entered rou­tine clinical use as an anticoagulant drug.
In parallel with clinical studies, extensive chemical and biochemical investiga­tions have been undertaken, contributing to the elucidation of the molecular basis of the anticoagulant and antithrombotic activities of heparin and heparin-like gly­cosaminoglycans (GAGs), such as heparan sulfate (HS) and dermatan sulfate (DS), in particular regarding their role in the coagulation system. The mechanism of the interaction of heparin and DS with two key proteins of the coagulation process, antithrombin (AT) and heparin cofactor II (HCII), and the subsequent enhance­ment of inactivation of the two key coagulation enzymes, factor Xa (fXa) and throm­bin (also named fIIa) has been unraveled at the molecular level.
The wealth of knowledge acquired, especially from the mid-1970s onward, has led to the development of low molecular weight heparins (LMWHs) derived from
353
Carbohydrate-Based Therapeutics, First Edition. Edited by Roberto Adamo and Luigi Lay. © 2024 WILEY-VCH GmbH. Published 2024 by WILEY-VCH GmbH.
11 Carbohydrate-Based Antithrombotics
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
354
unfractionated heparin (UFH) through distinct chemical or enzymatic depolymeri­zation processes and to a unique pentasaccharide obtained by chemical synthesis, as distinct drugs.
11.2 Antithrombotic Drugs
Under physiological conditions, blood flows smoothly and efficiently in the arteries and veins, but if a clot or thrombus breaks free from the vessel wall and obstructs blood flow, the result–termed thrombosis–can have serious, even lethal, conse­quences. Thrombosis can occur both in arteries, which carry blood from the heart to the rest of the body, as well as in veins, which carry blood from the body back to the heart. Arterial thrombosis can result in a heart attack when it occurs in coronary arteries, or in stroke when it occurs in blood vessels in the brain. Venous thrombosis can lead to DVT, often in the legs, groin or arms, and later to PE: DVT and PE are known collectively as venous thromboembolism (VTE). Both arterial and venous thromboses are major healthcare concerns, causing an estimated 18 million deaths worldwide each year[5].
The most important components of a thrombus are platelets and fibrin, the latter being the final product of the coagulation cascade and is a protein that forms a mesh encapsulating a high concentration of red blood cells. Both platelets and fibrin sta­bilize the thrombus and prevent it from breaking down, whereas fibrin predomi­nates in venous thrombi, and platelets are the main component of arterial clots. Accordingly, two classes of antithrombotic drugs have been developed; antiplatelet drugs and anticoagulants. Whereas the former prevents platelets from clumping, anticoagulants slow down clotting by reducing fibrin production and preventing the formation and growth of clots. All carbohydrate-based antithrombotic agents of a GAG nature, such as heparin, DS, LMWHs, and fondaparinux, together with drugs based on GAG mixtures, share this latter mode of action. Defibrotide (DF) and pen­tosan polysulfate (PPS), the only non-GAG antithrombotic drugs considered here, have a broader and more complex spectrum of action.
11.3 Heparin
Heparin originates in mammalian mast cell granules as a large (about 80 kDa) poly­meric component of the proteoglycan serglycin[6]. Its biosynthesis begins with the formation of a tetrasaccharide linkage region, which is synthesized from the proteo­glycan core protein and continues with the alternating addition of 1→4linked α-N­acetyl--glucosamine (GlcNAc) and β--glucuronic acid (GlcA), which leads to linear polysaccharide chain elongation. Immediately after polymerization, the sequential and coordinated action of a series of enzymes gives rise to important enzymatic modifications to the sequence. First, N-deacetylase–N-sulfotransferase partially removes the N-acetyl group from GlcNAc by simultaneously adding a sul­fate group (GlcNS), and then uronyl C-5 epimerase converts some GlcA into
11.3 Heparin
α--iduronic acid (IdoA) and various O-sulfotransferases catalyze the addition of sulfate groups at position 2 of IdoA, 6 of glucosamine or, less frequently, position 3 of glucosamine. The final result is the formation of structural domains with differ­ent substitution patterns and sulfation degrees[7]. Such an array of structural fea­tures can generate potentially a total of 48 different disaccharide combinations, but due to the restrictions of the biosynthetic route, only 23 disaccharides have been identified to date in heparin[8]. Based on the analysis of HS/heparin biosynthetic enzymes, a biosynthetic scheme structured in two branches has been proposed, the major one containing commonly occurring IdoA–GlcNS disaccharides, and the minor one involving less represented structures, such as IdoA–GlcNAc [9]. The nodal aspect of this scheme arises from the different efficiency with which epimer­ase converts GlcA–GlcNS into IdoA–GlcNS and GlcA–GlcNAc into IdoA–GlcNAc.
Following mast cell activation and consequent degranulation, heparin is released in the extracellular matrix of endothelium and partially hydrolyzed by heparanase, an endo-β-glucuronidase into fragments ranging in mass from 5 to 30 kDa[10], resulting in a mixture of highly heterogenous polymeric chains arising from both the different molecular weight as well as the number and position of sulfate groups of the constituent disaccharides. The main repeating disaccharide structure of the resulting polymer is the trisulfated unit [-4)-α--IdoA2S (1→4) α--GlcNS,6S-(1-], which constitutes the regular polymer regions, accounting for more than 70% of heparin chains and resulting in an overall degree of sulfation of about 2.4 per disac­charide[11, 12]. The remaining 30% of the heparin polymer, constituting the so­called irregular regions, has a more complex composition, including both less O-sulfated and N-acetylated domains, and an important pentasaccharide sequence, containing a 3-O-sulfated glucosamine, which interestingly, is usually preceded by an un-sulfated IdoA residue, IdoA–[GlcNAc,6S–GlcA–GlcNS,3S,6S–IdoA2S– GlcNS,6S–][13, 14]. Such a pentasaccharide, also called AGA*IA, with the asterisk indicating the peculiar 3-O sulfation, is endowed with a high affinity for the plasma protein AT. The structures of the basic disaccharide units, together with the AT-binding pentasaccharide are shown in Figure11.1. Despite the observation that irregular regions do not appear to be distributed in an orderly manner, a low- sulfated domain resides close to the original heparin core protein [15]. Moreover, the 3-O-sulfated pentasaccharide turns out to be enriched toward the nonreducing ter­minus of the heparin chain[16–19], in agreement with the finding that NMR sig­nals typically associated with the “linkage region” [20] are missing in heparin fractions with high affinity for AT[21]. In contrast, other studies have suggested a random distribution[22].
The heterogeneity of heparin can be related to the species and organs of origin and to the process of production. Heparins from different tissues and/or animal sources appear to have different IdoA2S and IdoA content. In particular, the trisul­fated disaccharide comprises up to 90% of bovine lung heparin extracts, an organ that was formerly a major source of heparin, whereas it represents about 75% of porcine mucosa, which has largely replaced bovine lung as the principal source of clinical heparin. Heparins from various animal origins also exhibit distinct levels of the antithrombin binding pentasaccharide sequence (ATBPS). Heparins extracted
355